MedPath

Multiple Dose Study of MK-6024 in Healthy Japanese Participants

Phase 1
Conditions
onalcoholic steatohepatitis
Registration Number
JPRN-jRCT2031210703
Lead Sponsor
Yoshiyuki Tanaka
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Male
Target Recruitment
20
Inclusion Criteria

Healthy male aged 20 to 65 years old with BMI 23 to 40 kg/m2

Exclusion Criteria

Has a history of clinically significant abnormalities or diseases

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
AEs and AEs leading to discontinuation
Secondary Outcome Measures
NameTimeMethod
Following serum PK parameters<br>-Following 4th, 8th, 12th and last (16th) doses: Tmax, Cmax, AUC0-tau<br>-Following 16th dose: t1/2, CL/F, Vz/F <br>-Following 3rd, 4th, 7th, 8th, 11th to 16th doses: Ctrough
© Copyright 2025. All Rights Reserved by MedPath